Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | Multiple myeloma MRD assessment

Fengyan Jin • 14 Sep 2019
IMW 2019
Multiple Myeloma

Prof Fengyan Jin of Jilin University, Jilin, China, outlines the issues with current criteria regarding (measurable residual disease) MRD testing within clinical trials, namely the depth of MRD sensitivity, which cannot always be reached, and the suggested duration of MRD. Recorded at the International Myeloma Workshop (IMW) 2019, in Boston, MA.

Related Videos

1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals